|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/18/22 QSAM Biosciences, Inc. 8-K:3,5,9 11/14/22 14:275K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 45K 2: EX-10.1 Material Contract HTML 15K 3: EX-10.2 Material Contract HTML 14K 4: EX-10.3 Material Contract HTML 15K 5: EX-10.4 Material Contract HTML 16K 9: R1 Cover HTML 41K 12: XML IDEA XML File -- Filing Summary XML 14K 10: XML XBRL Instance -- form8-k_htm XML 14K 11: EXCEL IDEA Workbook of Financial Reports XLSX 8K 7: EX-101.LAB XBRL Labels -- qsam-20221114_lab XML 97K 8: EX-101.PRE XBRL Presentations -- qsam-20221114_pre XML 64K 6: EX-101.SCH XBRL Schema -- qsam-20221114 XSD 13K 13: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 14: ZIP XBRL Zipped Folder -- 0001493152-22-032824-xbrl Zip 33K
Exhibit 10.4
AMENDMENT #1 TO
EMPLOYMENT AGREEMENT
THIS AMENDMENT #1 dated November 14, 2022 (the “Amendment”) to the EMPLOYMENT AGREEMENT (the “Agreement”) dated as of December 6, 2021, by and between QSAM Biosciences, Inc. (the “Company”), and Namrata Chand (the “Executive”).
RECITALS
WHEREAS, the Company and the Executive agree that it is in the best interest of the Company and its shareholders to settle accrued liabilities and temporarily reduce overhead expenses of the Company; and
WHEREAS, the Company and the Executive desire to amend the Executive’s employment agreement dated December 6, 2021 to help achieve these goals.
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and promises contained herein, the parties, each intending to be legally bound hereby, agree as follows:
| 10. | Deferred Salary Paid in Restricted Stock. |
(j) As of September 30, 2022, the Executive has deferred a total of $123,333.33 in Base Salary (the “Deferred Salary”). The Executive agrees hereby to accept as payment in full for the Deferred Salary a cash amount of $24,667 and 27,407 shares of common stock (the “Stock Compensation”), subject to the restrictions and forfeiture provisions set forth below. The Stock Compensation represents 125% of the total amount of the Deferred Salary as of September 30, 2022 not being repaid in cash to the Executive, as converted into common shares at $4.50 per share, representing the price paid by unaffiliated third parties for common shares in the Company’s current private placement offering.
(k) The Stock Compensation shall be restricted and subject to forfeiture as follows: Until such time that the Company successfully closes $5 million in a single fundraising (the “Trigger Event”), which may be completed in one or more closings over a period of no more than 90 days, the Stock Compensation may not be sold, transferred or otherwise disposed by the Executive. Upon the occurrence of a Trigger Event, the Stock Compensation shall be fully vested and may be sold or transferred by the Executive, subject to applicable SEC rules and regulations. If the Trigger Event does not occur within 36 months of the date of this Amendment, the Stock Compensation shall be forfeited and returned to the Company. The Stock Compensation shall not terminate or be forfeited upon death or disability of the Executive, or her termination without cause or for good reason, as defined in the Agreement.
(l) Upon the occurrence of a timely Trigger Event, the Company shall withhold a number of shares equal to the Executive’s tax liability related to the payment of the Stock Compensation, based on a price equal to the higher of $4.50 per share or the closing price of the Company’s common stock as of the date of public announcement of the Trigger Event. The Company shall pay such taxes through normal payroll procedures on behalf of the Executive.
| 11. | Future Base Compensation |
(m) Effective as of October 1, 2022, the Executive accepts as her interim base salary an amount of $120,000 per year, which shall increase to $125,000 per year as of the next payroll period after the Company completes $2 million in funding in its current private placement (the “Interim Base Salary”, which is further defined in Section 2.b., below).
(n) Upon the occurrence of a Trigger Event, as defined in Section 1 above, the Executive’s Interim Base Salary shall automatically be increased to $170,000 per year.
C:
(o) Upon the Company raising a minimum of $7.5 million in a single equity financing round, the Executive’s Interim Base Salary shall automatically be set to the Base Salary rate of $225,000 per year, and the definition of Base Salary as set forth in Section 4.1 of the Agreement is amended hereby. Until such time, the difference between the Base Salary and the Interim Base Salary shall not accrue nor be owed to the Executive.
(p) The existence and payment of the Interim Base Salary shall not change the Executive’s termination and severance terms, as set forth in Sections 7 and 8 of the Agreement, which shall continue to provide the Executive the protection of receiving a multiple of her full contracted Base Salary, as amended hereby, in the event of termination without cause or termination for good reason.
| 12. | Increased Transaction Bonus. |
(a) In consideration for the agreed upon reduced compensation set forth in Section 2 of this Amendment, the Transaction Bonus set forth in Section 4.3 of the Agreement shall be increased hereby to point five percent (0.5%).
(b) All other terms and conditions in Section 4.3 of the Agreement shall remain the same and unchanged.
| 13. | Miscellaneous Terms |
(m) All terms not defined herein shall have the meanings given to them in the Agreement. To the extent that terms and provisions herein conflict with those in the Agreement, this Amendment shall govern.
(n) This Amendment shall be binding upon, and inure to the benefit of, the parties hereto and their heirs, personal representatives, successors and assigns; provided that the Executive’s duties hereunder are of a personal nature and may not be assigned.
(o) This Amendment shall be governed by and construed in accordance with the laws of the State of Texas.
(p) This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Agreement.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment to the Employment Agreement as of the date and year first above written.
| QSAM Biosciences, Inc. | ||
| By: | /s/ Douglas Baum | |
| Name: | Douglas Baum | |
| Title: | CEO | |
| THE EXECUTIVE | ||
| /s/ Namrata Chand | ||
| Namrata Chand | ||
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/18/22 | |||
| For Period end: | 11/14/22 | 10-Q | ||
| 10/1/22 | ||||
| 9/30/22 | 10-Q, 8-K | |||
| 12/6/21 | 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/20/24 QSAM Biosciences, Inc. 10-K 12/31/23 55:7.4M M2 Compliance LLC/FA 3/30/23 QSAM Biosciences, Inc. 10-K 12/31/22 60:7.4M M2 Compliance LLC/FA |